Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study

PHASE3CompletedINTERVENTIONAL
Enrollment

6,505

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Chronic Heart Failure
Interventions
DRUG

Ivabradine

2.5mg, 5mg or 7.5mg tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 42 months.

DRUG

Placebo

Matching placebo tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 42 months.

Trial Locations (2)

75013

Hôpital Pitié-Salpétrière, Paris

S 41685

Göteborg University, Gothenburg

All Listed Sponsors
lead

Institut de Recherches Internationales Servier

OTHER

NCT02441218 - Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study | Biotech Hunter | Biotech Hunter